Valeant Pharmaceuticals International Inc. on Monday said three high-level executives are leaving the company, including the former chief financial officer. Rob Rosiello, who stepped down in August as CFO but stayed with the Valeant, is quitting along with Anne Whitaker and Ari Kellen, both executive vice presidents and company group chairmen. The company also named William Humphries as executive vice president of dermatology, effective Jan. 2. The pharmaceutical company's stock skidded 86% in 2016 in the wake of a drug-pricing scandal. Valeant shares edged up 0.3% after hours.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.